Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| NCI-2021-14062 | Registry Identifier | CTRP (Clinical Trial Reporting Program) |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This clinical trial estimates the abuse liability of nicotine pouches with varying nicotine concentrations relative to cigarette smoking in Appalachian, Ohio and Ohio smokers. Nicotine pouches are a novel tobacco product with potential to reduce or increase the harm of tobacco use. Evaluating nicotine pouches abuse liability among smokers in Ohio including the unique demographic of Appalachia may clarify the public health effect of NPs in Appalachian Ohio and across Ohio. Results may inform public health efforts, policy, and clinical care aimed at reducing tobacco-related disparities.
Aim 1:
PRIMARY OBJECTIVE:
I. To estimate the abuse liability of nicotine pouches (NPs) with varying nicotine concentrations relative to cigarette smoking.
SECONDARY OBJECTIVE:
I. To clarify the public health effect of NPs in Appalachian Ohio.
EXPLORATORY OBJECTIVES:
I. To estimate the abuse liability of NPs with varying nicotine concentrations relative to cigarette smoking by measuring nicotine pharmacokinetics.
II. To estimate the abuse liability of NPs with varying nicotine concentrations relative to cigarette smoking by measuring subjective effects.
III. To estimate the abuse liability of NPs with varying nicotine concentrations relative to cigarette smoking by measuring intentions to use and switch to NPs.
OUTLINE: Patients are randomized to 1 of 3 arms.
ARM I: Patients receive lower dose nicotine pouch orally (PO) over 30 minutes at visits 1, 2, and 3.
ARM II: Patients receive higher dose nicotine pouch PO over 30 minutes at visits 1, 2, and 3.
ARM III: Patients smoke usual brand of cigarettes, taking one puff every 30 seconds over 5 minutes at visits 1, 2, and 3.
Aim 2:
PRIMARY OBJECTIVE:
I. To understand the pharmacokinetic difference between tobacco-derived and synthetic NPs.
SECONDARY OBJECTIVE:
I. To clarify the public health effect of NPs on adult smokers
EXPLORATORY OBJECTIVES:
I. To understand the differences in abuse liability between tobacco-derived and synthetic NPs by measuring nicotine pharmacokinetics.
II. To understand the differences in abuse liability between tobacco-derived and synthetic NPs by measuring subjective effects.
III. To estimate the abuse liability of tobacco-derived vs. synthetic NPs by measuring intentions to use and switch to NPs.
OUTLINE: Patients are randomized to 1 of 3 arms.
ARM I: Patients receive a 3mg dose nicotine pouch orally (PO) over 30 minutes at visits 1, 2, and 3.
ARM II: Patients receive a 3mg dose nicotine pouch PO over 30 minutes at visits 1, 2, and 3.
ARM III: Patients receive a 3mg dose nicotine pouch PO over 30 minutes at visits 1, 2, and 3.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Aim 1: Arm I (lower dose nicotine pouch) | Experimental | Patients receive lower dose nicotine pouch PO over 30 minutes at visits 1, 2, and 3. |
|
| Aim 1: Arm II (higher dose nicotine pouches) | Experimental | Patients receive higher dose nicotine pouch PO over 30 minutes at visits 1, 2, and 3. |
|
| Aim 1: Arm III (cigarette smoking) | Active Comparator | Patients smoke usual brand of cigarettes, taking one puff every 30 seconds over 5 minutes at visits 1, 2, and 3. |
|
| Aim 2: Arm I (3mg NP) | Experimental | Patients receive nicotine pouch PO over 30 minutes at visits 1, 2, and 3. |
|
| Aim 2: Arm II (3mg NP) | Experimental | Patients receive nicotine pouch PO over 30 minutes at visits 1, 2, and 3. |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Cigarette Smoking | Behavioral | Smoke preferred brand of cigarette |
| |
| Measure | Description | Time Frame |
|---|---|---|
| Evaluate plasma nicotine concentration at t=30 minutes for each product. | Up to 6 months |
| Measure | Description | Time Frame |
|---|---|---|
| Aim 1: Public health effect of NPs in Appalachian Ohio - if NPs can be used as a substitute for cigarette smoking | Data collected will show if NPs are a viable substitute for cigarette smoking. | Up to 6 months |
| Evaluate plasma nicotine concentrations at t=5 through t=90 minutes |
| Measure | Description | Time Frame |
|---|---|---|
| Aim 1 and 2: Nicotine pharmacokinetics | Will use linear or logistic mixed effects regression models (with a random subject effect) to assess the main effects of product on plasma nicotine delivery. | Up to 6 months |
| Subjective effects - likability and substitutability of product compared to cigarette smoking will be assessed |
Aim 1 Inclusion Criteria:
Exclusion Criteria:
Aim 2 Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Brittney L Keller-Hamilton, PhD, MPH | Ohio State University Comprehensive Cancer Center | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Ohio State University Comprehensive Cancer Center | Columbus | Ohio | 43210 | United States |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 37964431 | Background | Keller-Hamilton B, Alalwan MA, Curran H, Hinton A, Long L, Chrzan K, Wagener TL, Atkinson L, Suraapaneni S, Mays D. Evaluating the effects of nicotine concentration on the appeal and nicotine delivery of oral nicotine pouches among rural and Appalachian adults who smoke cigarettes: A randomized cross-over study. Addiction. 2024 Mar;119(3):464-475. doi: 10.1111/add.16355. Epub 2023 Nov 14. | |
| 38713545 |
| Label | URL |
|---|---|
| The Jamesline | View source |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Type | Includes Protocol | Includes SAP | Includes ICF | Document Label | Document Date | Document Uploaded Date | Document File Name |
|---|---|---|---|---|---|---|---|
| Prot_SAP | Yes | Yes | No | Study Protocol and Statistical Analysis Plan | Nov 1, 2022 |
Not provided
Not provided
Not provided
Not provided
Not provided
| Aim 2: Arm III (3mg NP) | Experimental | Patients receive nicotine pouch PO over 30 minutes at visits 1, 2, and 3. |
|
| Nicotine Oral Pouch |
| Drug |
Given lower dose nicotine pouch |
|
|
| Nicotine Oral Pouch | Drug | Given higher dose nicotine pouch |
|
|
| Questionnaire Administration | Other | Ancillary studies |
|
| Nicotine Oral Pouch | Drug | Given 3mg nicotine pouch (Aim 2) |
|
|
| Nicotine Oral Pouch | Drug | Given 3mg nicotine pouch (Aim 2) |
|
|
| Nicotine Oral Pouch | Drug | Given 3mg nicotine pouch (Aim 2) |
|
|
| Up to 6 months |
| Evaluate withdrawal relief at t=5 through t=90 minutes | We measure withdrawal relief using the Minnesota Withdrawal Scale (MNWS). We administer this questionnaire at each timepoint along the standardized scale of t=0, t=5, t=15, t=30, t=60 and t=90. The MNWS includes a minimum value of "none" and a maximum value or "severe." The higher scores indicate increased withdrawal symptoms and lower scores indicate lessened or no withdrawal symptoms. | Up to 6 months |
| Evaluate product appeal across all 3 products | Product appeal will be assessed using several scales, including the Modified E-Cigarette Smoking Questionnaire (mCEQ), the Product Evaluation Scale (PES), the Adapted Drug Effects Liking Scale, and the Study Product Effects Liking Scale which are administered after the final timepoint of each study visit. For both the mCEQ and PES, the minimum scale value is "not at all" and the maximum scale value is "extremely." Higher scores can mean both better or worse depending on the question. Ex: "Was using your smokeless tobacco satisfying?" and "Did using your smokeless tobacco make you nauseous?" are both questions on each scale, so a higher score would vary in meaning based on the question. For the Adapted Drug Effects Liking and Study Product Effects Liking scales, minimum values include "not at all" and maximum value includes "very pleasant." With the exception of one question on the Study Product Effects Liking Scale, a higher score indicates increased enjoyment of the product. | Up to 6 months |
Will use linear or logistic mixed effects regression models (with a random subject effect) to assess the main effects of product on subjective effects. |
| Up to 6 months |
| Aim 1: Intentions to use and switch to NPs - quit intentions will be assessed using a 10 question survey | Will use linear or logistic mixed effects regression models (with a random subject effect) to assess the main effects of product behavioral intentions. | Up to 6 months |
| Aim 2: Public health effect of NPs in adult smokers - if NPs can be used as a substitute for cigarette smoking. | Public health impact of NPs in adult smokers as an alternative for cigarette smoking. | Up to 6 months |
| Background |
| Keller-Hamilton B, Curran H, Alalwan M, Hinton A, Brinkman MC, El-Hellani A, Wagener TL, Chrzan K, Atkinson L, Suraapaneni S, Mays D. Evaluating the Role of Nicotine Stereoisomer on Nicotine Pouch Abuse Liability: A Randomized Crossover Trial. Nicotine Tob Res. 2025 Mar 24;27(4):658-665. doi: 10.1093/ntr/ntae079. |
| May 16, 2024 |
| Prot_SAP_000.pdf |
| ICF | No | No | Yes | Informed Consent Form | May 31, 2022 | Mar 12, 2024 | ICF_001.pdf |
| ID | Term |
|---|---|
| C106866 | WD repeat containing planar cell polarity effector |
Not provided
Not provided
Not provided